Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Dbait + Fluorouracil + Oxaliplatin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dbait||Dbait is a nanoparticle drug containing short interfering DNA that mimic DNA double strand breaks, which has been demonstrated to result in activation of the DNA damage response with anti-metastatic tumor activity in liver (PMID: 26637369, PMID: 31858836, PMID: 31275862).|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 11||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Oxaliplatin||Eloxatin||Diaminocyclohexane Oxalatoplatinum||Chemotherapy - Platinum 6||Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Dbait + Fluorouracil + Oxaliplatin||Preclinical||Actionable||In a preclinical study, Dbait with Eloxitan (oxaliplatin) and Adrucil (5-fluorouracil) resulted in decreased proliferation of human colorectal cancer cell lines in culture (PMID: 26637369).||26637369|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|